Hyperliquid Strategies reports $152.5M Q3 profit on $198.4M HYPE token gains, 20M treasury

The company reported a net profit of $152.5 million for the quarter ended March 31, 2026, driven primarily by $198.4 million in unrealized gains on HYPE tokens, partially offset by a $42.7 million increase in deferred tax expense. Revenue consisted of $2.6 million in staking revenue and $1.0 million in interest income, with $7.2 million in operating expenses.

For the nine months ended March 31, 2026, the company reported a net loss of $165.4 million, driven by $64.0 million in net unrealized losses on HYPE tokens, a one-time $35.6 million IPR&D write-off related to the legacy Sonnet business acquisition, and a $60.5 million increase in deferred tax expense. Revenue totaled $5.0 million ($3.1 million staking, $1.9 million interest) against $10.7 million in operating expenses.

As of March 31, 2026, the company held total assets of $809.4 million, including $113.1 million in cash and $689.0 million in HYPE tokens (18.83 million tokens at $36.60 per token). Stockholders' equity stood at $743.5 million with no debt. As of April 29, 2026, the treasury had grown to 20.0 million HYPE tokens with $103 million in remaining cash.

Since inception on December 2, 2025, the company deployed $216.0 million to acquire approximately 7.3 million HYPE tokens (bringing total holdings to 20.0 million) and $10.5 million to repurchase approximately 3.0 million PURR shares at an average cost of $3.42 per share. The company raised $38.4 million by issuing PURR shares at an average price of approximately $6.31 under its committed equity facility.

The company announced a validator partnership with Unit, described as one of the leading Hyperliquid deployers, and completed the disposition of the majority of its legacy bio-tech operations.

Hyperliquid Strategies deployed $226.5 million since its December 2025 public listing: $216.0 million to acquire 7.3 million HYPE tokens (average price $29.53), bringing total holdings to 20.0 million HYPE tokens, and $10.5 million to repurchase 3.1 million PURR shares (average cost $3.42). The company retains approximately $103 million in cash and has no debt. This represents the company's core treasury strategy of accumulating HYPE tokens, the native token of the Hyperliquid blockchain.

Hyperliquid Strategies disposed of its legacy biotech assets (Sonnet) by contributing the majority of those assets plus $2.3 million (and a subsequent $1 million) to Guidant BioTherapeutics in exchange for a 40% equity stake. This transaction removes non-core biotech operations and associated costs and liabilities, allowing the company to focus exclusively on its HYPE token treasury strategy while preserving modest upside through the Guidant equity stake. The Guidant team will manage both new initiatives and legacy wind-down obligations.

As of March 31, 2026 (Q3 fiscal quarter end), the company held 18.8 million HYPE tokens valued at $36.60 per token, cash and cash equivalents primarily invested in treasury bills and money market funds, and zero debt. The balance sheet reflects a deferred tax liability based on the $36.60 HYPE token price. The income statement disclosed staking revenue from HYPE tokens, an unrealized loss on HYPE tokens for the quarter, a loss on HYPE contributed related to the decline in token value from initial commitment to transaction completion, an IPR&D write-off of excess purchase price from the legacy asset acquisition, and deferred tax expense.